Fig. 3From: Effect of etanercept therapy on psoriasis symptoms in patients from Latin America, Central Europe, and Asia: a subset analysis of the PRISTINE trialPercentage of PASI 50 a, 75 b, and 90 c responders by treatment group (LOCF data). *p < 0.05; †p < 0.01. BIW: twice weekly; LOCF: last observation carried forward; PASI: Psoriasis Area and Severity Index; QW: once weeklyBack to article page